Himadri Speciality Chemical Limited
Momentum (92/100) does the heavy lifting; valuation (0/100) is the drag.
ExpensiveOvervaluedHimadri Speciality Chemical Limited earns a Hold from StocksWizard, with a blended score of 45/100. At ₹769.9 it trades above our blended DCF and relative-multiples fair value of ₹384.95, about 50% downside to that estimate — we read it as overvalued by 50%. On 49.5x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 4% below its 52-week high of ₹800.9 and 83% above the low of ₹421.43. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹720 implies about 6% downside across 1 analysts. It clears 7 of 11 investability checks, with durability 74, valuation 0 and momentum 92 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹307.96.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-3.87% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- No data: ROE above 15%
- Pass: Low debt (D/E < 0.5): 0.16x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 28%
- Pass: Earnings growing: 25%
- Pass: Net margin ≥ 10%: 16.1%
- No data: Current ratio > 1.5
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 17.18
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter59.9%
- Institutions6.5%
- Public & other33.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (16.1%).
- Financially solid — Altman Z 17.18.
Opportunities
- Earnings growing (25% YoY).
- Revenue growing (28% YoY).
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Himadri Speciality Chemical Limited
Himadri Speciality Chemical Limited manufactures and sells carbon materials and chemicals across India and international markets. The company operates through two segments: Carbon Materials and Chemicals, and Power. Its product portfolio includes anode materials, LFP cathodes, and recycling materials.
Himadri Speciality Chemical Limited — frequently asked questions
Is Himadri Speciality Chemical Limited a buy, hold or sell?
StocksWizard currently rates Himadri Speciality Chemical Limited (HSCL) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Himadri Speciality Chemical Limited's fair value?
Our blended DCF and relative-valuation model estimates Himadri Speciality Chemical Limited's fair value at about ₹384.95, versus a current price of ₹769.9 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Himadri Speciality Chemical Limited financially healthy?
Himadri Speciality Chemical Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Himadri Speciality Chemical Limited's share price performed?
Himadri Speciality Chemical Limited is up 27% over three months, and last traded at ₹769.9. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.